Caprelsa - direct healthcare professional communication (DHPC)

Vandetanib

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Caprelsa (vandetanib): Restriction of indication

Key facts

• Medicine name:
  Caprelsa
• Active substance:
  Vandetanib
• Therapeutic area (MeSH):
  Thyroid Neoplasms
• Procedure number:
  EMEA/H/C/002315/II/0043
• Regulatory outcome:
  Variation
• DHPC type:
  Restriction of indication
• Human ATC codes:
  L01XE